These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 6196202)
1. Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815. Marchand M; Caspar P; Boon T Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1529-37. PubMed ID: 6196202 [TBL] [Abstract][Full Text] [Related]
2. Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidine. Frost P; Liteplo RG; Donaghue TP; Kerbel RS J Exp Med; 1984 May; 159(5):1491-501. PubMed ID: 6201588 [TBL] [Abstract][Full Text] [Related]
3. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. Uyttenhove C; Van Snick J; Boon T J Exp Med; 1980 Nov; 152(5):1175-83. PubMed ID: 6776226 [TBL] [Abstract][Full Text] [Related]
4. Tumour cell variants with increased immunogenicity obtained by mutagen treatment. Boon T; Maryanski J Cancer Surv; 1985; 4(1):135-48. PubMed ID: 3879855 [TBL] [Abstract][Full Text] [Related]
5. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. Maryanski JL; Marchand M; Uyttenhove C; Boon T Int J Cancer; 1983 Jan; 31(1):119-23. PubMed ID: 6187698 [TBL] [Abstract][Full Text] [Related]
6. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. Maryanski JL; Boon T Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608 [TBL] [Abstract][Full Text] [Related]
7. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Wölfel T; Van Pel A; De Plaen E; Lurquin C; Maryanski JL; Boon T Immunogenetics; 1987; 26(3):178-87. PubMed ID: 3114137 [TBL] [Abstract][Full Text] [Related]
8. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids. Maryanski JL; Szpirer J; Szpirer C; Boon T Somatic Cell Genet; 1983 May; 9(3):345-57. PubMed ID: 6407125 [TBL] [Abstract][Full Text] [Related]
9. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. Boon T; Van Snick J; Van Pel A; Uyttenhove C; Marchand M J Exp Med; 1980 Nov; 152(5):1184-93. PubMed ID: 6776227 [TBL] [Abstract][Full Text] [Related]
10. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. De Plaen E; Lurquin C; Van Pel A; Mariamé B; Szikora JP; Wölfel T; Sibille C; Chomez P; Boon T Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2274-8. PubMed ID: 3127830 [TBL] [Abstract][Full Text] [Related]
11. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Maryanski JL; Van Snick J; Cerottini JC; Boon T Eur J Immunol; 1982 May; 12(5):401-6. PubMed ID: 6178607 [TBL] [Abstract][Full Text] [Related]
12. Structure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic allele. Szikora JP; Van Pel A; Brichard V; André M; Van Baren N; Henry P; De Plaen E; Boon T EMBO J; 1990 Apr; 9(4):1041-50. PubMed ID: 2108859 [TBL] [Abstract][Full Text] [Related]
13. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. Uyttenhove C; Maryanski J; Boon T J Exp Med; 1983 Mar; 157(3):1040-52. PubMed ID: 6187879 [TBL] [Abstract][Full Text] [Related]
14. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens. Van Snick J; Maryanski J; Van Pel A; Parmiani G; Boon T Eur J Immunol; 1982 Nov; 12(11):905-8. PubMed ID: 6818041 [TBL] [Abstract][Full Text] [Related]
15. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. Van Pel A; Vessière F; Boon T J Exp Med; 1983 Jun; 157(6):1992-2001. PubMed ID: 6602203 [TBL] [Abstract][Full Text] [Related]
16. Mutagen-induced Imm+ variants: the need for viable and cloned Imm+ variants for effective protection against a primary murine tumor and its metastases. Sella A; Hunt B; Frost P Clin Exp Metastasis; 1989; 7(1):97-105. PubMed ID: 2491744 [TBL] [Abstract][Full Text] [Related]
17. Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice. Van Pel A; Georlette M; Boon T Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5282-5. PubMed ID: 291945 [TBL] [Abstract][Full Text] [Related]
18. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level. Sensi M; Orosz CG; Bach FH J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778 [TBL] [Abstract][Full Text] [Related]
19. Effects of mutagens on the immunogenicity of tumor cells: comparison of cell surface changes induced by 5-azacytidine and N-methyl-N'-nitro-N-nitrosoguanidine. Altevogt P Cancer Res; 1986 Jun; 46(6):2912-6. PubMed ID: 2421887 [TBL] [Abstract][Full Text] [Related]
20. Immunogenic variants obtained by mutagenesis of mouse Lewis lung carcinoma. Recognition of variant-specific antigens by cytolytic T lymphocytes. Vessière F; Georlette M; Warnier G; Leclerc JC; Van Pel A; Boon T Eur J Cancer Clin Oncol; 1982 Sep; 18(9):867-74. PubMed ID: 6185345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]